Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”

Shionogi said on June 30 that it has expanded its collaboration with Osaka University spinout StemRIM for redasemtide, a compound described as a “regeneration-inducing medicine,” aiming to conduct investigator-led clinical studies targeting new indications. Redasemtide, an HMGB1 peptide otherwise known...read more